



## Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

October 5, 2022

Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Oct. 5, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37<sup>th</sup> Annual Meeting taking place November 8-12, 2022 in Boston, MA.

### Poster Presentations:

**Abstract Title:** Innate-Enhanced Chimeric Adaptors (CAAd): A Newly-Described Approach for Augmenting Potency of  $\gamma\delta$  T Cell Immunotherapy

**Poster/Abstract Number:** 198

**Presenting Author:** Marissa Herrman, Ph.D.

**Date/Time:** November 11, 2022 from 9:00am – 9:00pm EST

**Title:** Preclinical Discovery and Characterization of Allogeneic anti-PSMA  $\gamma\delta$  CAR T Therapy for Prostate Cancer

**Poster/Abstract Number:** 203

**Presenting Author:** Nitya S. Ramadoss, Ph.D.

**Date/Time:** November 10, 2022 from 9:00am – 9:00pm EST

**Abstract Title:** Allogeneic "off-the-shelf"  $\gamma\delta$  T cells modified with CD27- containing CAR for targeting CD70+ cancers

**Poster/Abstract Number:** 246

**Presenting Author:** Kevin P. Nishimoto, Ph.D.

**Date/Time:** November 11, 2022 from 9:00am – 9:00pm EST

**Abstract Title:** Preclinical Discovery and Evaluation of Allogeneic "off-the-shelf"  $\gamma\delta$  CAR T Cells Targeting B7-H6+ Tumors

**Poster/Abstract Number:** 247

**Presenting Author:** Kevin P. Nishimoto, Ph.D.

**Date/Time:** November 10, 2022 from 9:00am – 9:00pm EST

The abstracts will be available in a [Journal for ImmunoTherapy of Cancer \(JITC\)](#) supplement, which will be published on Monday, November 7 at 8:00am EST on [www.sitcancer.org](http://www.sitcancer.org).

### R&D Webcast

Adicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.

### About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic chimeric antigen receptor (CAR) and adaptor (CAAd) gamma delta T cell therapies engineered to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at <http://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221005005195/en/): <https://www.businesswire.com/news/home/20221005005195/en/>

### Adicet Bio., Inc.

#### Investor and Media Contacts

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

[janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)

Source: Adicet Bio, Inc.